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The p7 protein of hepatitis C virus (HCV) functions as an ion channel in planar lipid bilayers, and its function is vital for the virus life cycle. In
this study, we replaced either the entire or partial p7 of genotype 2a (strain JFH1), an HCV strain that replicates and produces virus progeny in
vitro, with the corresponding regions of the p7 protein from genotype 1b (Australian isolate, HCV-A). Compared to wild type, the chimeric viruses
reached their peak of infectivity with a delay but they produced a comparable titer to the wild type virus and the progeny viruses were able to
infect naive permissive cells. Amantadine treatment of wild type and chimeric viruses reduced the virus titers by about 50% and 45%, respectively.
Therefore, in this study, for the first time, we demonstrated that genotype 2a (JFH1 strain) genome encoding a full-length genotype 1b p7 gene
produces infectious particles in vitro. These chimeric viruses are valuable instruments for comparative studies of the p7 proteins.
© 2006 Elsevier Inc. All rights reserved.Keywords: p7 protein; JFH1 strain; Chimeric virus; Hepatitis C virus; AmantadineIntroduction
Hepatitis C virus (HCV) is a major etiological agent of
chronic hepatitis, which can lead to hepatocellular carcinoma
and is currently the leading single indicator for liver
transplantation in the developed world. The threat posed to
the health systems in developed and developing countries by
HCV infection continues to grow at an alarming rate. In the
most recent report of WHO on HCV prevalence, it has been
estimated that 123 million individuals are infected with the virus
worldwide.
HCV is classified in the family Flaviviridae, genus Hepaci-
virus and is a small enveloped virus with a positive-sense single
stranded RNA genome. The genome encodes a polyprotein that
is co- and post-translationally cleaved into at least 10 structural
and nonstructural (NS) viral proteins (Fields et al., 1996). One of
these, the p7 protein, is a small, membrane-associated protein of
63 amino acids that is located at the junction of the structural and⁎ Corresponding author. Fax: +61 3 92822100.
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doi:10.1016/j.virol.2006.10.014NS proteins (Lin et al., 1994). Thus far, it has not been
determined if the p7 protein is a structural or an NS protein. The
protein is comprised of two tails located in the lumen of the
endoplasmic reticulum (ER), two hydrophobic transmembrane
α-helices, TM1 and TM2, and an intervening basic loop located
in the cytoplasm (Carrere-Kremer et al., 2002). Using plasmid
expression vectors, p7 has been shown to be mainly localized in
the endoplasmic reticulum (Carrere-Kremer et al., 2002; Griffin
et al., 2005) and possibly in mitochondrial membranes while a
small percentage of the over-expressed p7 protein was detected
in the plasmamembrane (Griffin et al., 2004). However, we have
recently shown that p7 is localized to the ER, not mitochondria,
in cells transfected with a replication-competent recombinant
genome of the JFH1 strain of HCV (Haqshenas et al., in press).
It has recently been shown that the p7 protein forms ion
channels in planar lipid bilayers (Griffin et al., 2003; Pavlovic
et al., 2003; Premkumar et al., 2004). p7 belongs to a family of
proteins known as viroporins, which homo-oligomerize to form
ion channels in cellular membranes (Gonzalez and Carrasco,
2003). Similar to that which has been shown for other viral ion
channel forming proteins like the influenza virus proteins, M2
Fig. 1. Ion channel activity of the HCV-A.p7 in planar lipid bilayers. (A) The
current across the lipid bilayer in the absence of protein. (B) Ion channel activity
of the full-length HCV-A.p7. (C) Ion channel activity of the HCV-A.p7 protein
in the presence of 100 μM amantadine.
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BM2 (Mould et al., 2003), and NB (Sunstrom et al., 1996),
HIV proteins Vpu (Ewart et al., 1996) and Vpr (Piller et al.,
1996), alphavirus 6K protein (Melton et al., 2002), Severe
Acute Respiratory Syndrome (SARS) coronavirus (SARS-
CoV) E protein (Wilson et al., 2004), GBV-B p7 (Premkumar
et al., 2006) and Dengue virus M protein (Premkumar et al.,
2005), the p7 protein seems to have an essential role in the
HCV life cycle. In an in vivo study, p7 was shown to be
essential for HCV replication as viral RNA with the p7 region
deleted or mutated was non-infectious in chimpanzees (Sakai
et al., 2003). However, p7 is dispensable for viral RNA
replication as replicons which lack the p7 gene replicate
efficiently (Blight et al., 2000; Lohmann et al., 1999). Therefore,
it is concluded that p7 is not required for efficient HCV genome
replication, but is essential for the production of infectious
virions (Sakai et al., 2003).
Recently, the H77 (Yi and Lemon, 2004) and JFH1 strains of
HCV genotypes of 1a and 2a, respectively, were demonstrated
to replicate and produce progeny virus in cell culture systems
(Lindenbach et al., 2005; Wakita et al., 2005; Yi et al., 2006;
Zhong et al., 2005). Very recently, chimeric JFH1 viruses
encoding the genotypes 1a, 1b and 3a structural proteins, p7 and
partial NS2 were also constructed (Koutsoudakis et al., 2006;
Pietschmann et al., 2006). Although these cell culture systems
will play a significant role to increase our understanding of the
molecular biology of HCV and drug discovery, there remains a
need for a cell culture system to discover ion channel inhibitors
and investigate their specific effects on the p7 protein.
Currently, there are no specific targeted antiviral agents
effective against HCV. The current treatment for HCV is a
combination of pegylated interferon-alfa and ribavirin, which is
only effective in about 50% of patients. This therapy produces
considerable side effects and can lead to the emergence of
resistant virus strains (Fargion et al., 2004). The p7 protein, as
an ion channel forming protein, is a potential target for ion
channel inhibitors. p7 ion channel activity in planar lipid
bilayers is inhibited by hexamethylene amiloride (Premkumar
et al., 2004), long-alkyl-chain iminosugar derivatives (Pavlovic
et al., 2003) and amantadine, which also inhibited p7 activity in
an hemadsorption assay (Griffin et al., 2003; Griffin et al.,
2004). In clinical trials, amantadine has been shown to
significantly increase the number of HCV-infected patients
who showed a sustained virological response (Berg et al., 2003;
Deltenre et al., 2004; Mangia et al., 2004) while other data have
not supported these findings (Thuluvath et al., 2004). These
contrasting findingsmay be a reflection of amantadine resistance
of the ion channel function of p7 found in some HCV strains
(Steinmann et al., 2005).
Collectively, there is an urgent demand for authentic cell
culture systems to examine ion channel inhibitors on the p7
protein of different genotypes. Therefore, in the current study,
we investigated if the JFH1 strain could be used as a backbone
to generate chimeric viruses encoding the p7 protein of
genotype 1b of HCV. Such chimeric viruses would be valuable
tools to investigate the specific effects of ion channel inhibitors
on the function of the p7 protein.Results
p7 protein of HCV-A of genotype 1b has amantadine-resistant
ion channel activity
Before the chimeric viruses were synthesized, we examined
the ability of HCV-A.p7 to form functional ion channels. As
shown in Fig. 1B, following the addition of the full-length p7
peptide to the CIS chamber of the planar lipid planar rig, ion
currents were detected after brief periods of stirring. This
indicates that the p7 has incorporated and formed ion channels in
the lipid bilayer separating the CIS and TRANS chambers.
Similarly, it was found that the N-terminal 38 residues
comprised of the lumenal tail, TM1, and the cytosolic loop
could form ion channels (data not shown). These data are in
agreement with the computer modeling showing that only TM1
is involved in the channel formation (Patargias et al., 2006). As
can be seen in Fig. 1C, amantadine at a final concentration of
100 μM did not block the ion channel activity of the protein.
The recombinant genomes are replication-competent
Before the generation of the chimeric viruses, we compared
the deduced amino acid sequences of the p7 of genotype 2a
(JFH1) and 1b (HCV-A). The sequences shared about 60%
identity in a pairwise alignment (Fig. 2). Two chimeric JFH1
cDNA constructs were generated, one encoding the partial and
the other one encoding the entire p7 gene of genotype 1b
(Fig. 3), in response to a previous report that the amino acid
sequences of the lumenal tails of p7 protein were crucial for
E2-p7 and p7-NS2 cleavage (Sakai et al., 2003).
In order to demonstrate that the chimeric genomes were
replication-competent, Huh7 cells were transfected with wild
Fig. 2. Comparison analysis of the deduced amino acid sequences of p7 proteins
of JFH1 and HCV-A isolates of HCV. The lumenal tails are shown in boxes.
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post-transfection by IF with anti-core antibody. The lysates of
the infected cells were also subjected to immunoblot analysis.
As shown in Fig. 4A, cells transfected with the recombinant
genomes showed an intense signal by IF. The positive cells
showed a core-specific punctuated cytoplasmic staining pattern
as described previously (Hope et al., 2002). In Western blot
analysis, a band with an approximate size of 20 kDa, consistent
with the molecular weight of the core protein, was observed in
the cells transfected with the wild type and chimeric genomes
(data not shown). As the control GNDJFH1 mutants failed to
generate any signal in either IF or Western blot, these data
indicate that the recombinant genomes were replication-
competent. Since the results generated from GNDJFH1 mutant
were identical to those from G-Fp7 and G-Pp7, in the next steps,
we only used GNDJFH1 as a control.
The chimeric genomes produce infectious particles
After transfection, the Huh7 cells were passaged to determine
if they were persistently infected. After each passage, the cells
were examined for core protein by IF. At the first passage, the
proportion of core antigen-positive cells in the culture
transfected with the wild type RNA slightly increased (from
40–50% to about 60–70%) while the proportion of positive cells
in the culture transfected with the chimeric genomes decreased
slightly (from 40–50% to about 30–40%, data not shown). High
numbers of non-adherent cells were noted continuously in the
culture transfected with the wild type RNA, while the Pp7 and
Fp7-transfected cells failed to show a CPE until passage 3. This
is consistent with the IF data showing that the percentage of core
antigen-positive cells in the wild type-transfected culture
remained at 90–100% until passage 5 and then declined sharply
to 10–20%. The cells became totally negative by passage 6. To
investigate if a virus-resistant cell subset dominated during the
course of infection, we re-exposed the cells to the virus and
showed that the cells were successfully re-infected (data not
shown). In the Pp7- and Fp7-transfected cells, the proportion ofFig. 3. Schematic representation of the wild type and chimeric JFH1 polyproteins.
domains (TM1 and TM2) and an intervening cytosolic loop. Hatched boxes indicate t
A.p7 to generate the partial (P-p7) and complete (F-p7) JFH1/HCV-A.p7 chimeras.positive cells declined to about 30% in passage 2 but increased
significantly in passage 3 (about 70–80% positive, data not
shown). About 30–50% of the cells were still positive for core
antigen at passage 7 when the experiment was concluded. To
determine if the supernatants of the cells were infectious, naive
Huh7 cells were infected with the supernatant fluid containing
the highest viral titers. Three days post-infection, the cells were
examined by anti-core-antigen IF test and shown to be positive
(Fig. 4A). The lysates of the infected cells were also subjected to
Western blot analysis and showed a band with an approximate
size of 20 kDa in the cells transfected with the wild type and
chimeric genomes (Fig. 4B).
We also examined the viral RNA titer in the cell culture
supernatant of each passage. As shown in Fig. 5A, the titer of the
wild type viral RNA in the supernatant increased at passage one
and remained high during the next passages before it gradually
decreased to undetectable levels at passage 7. In the case of the
chimeric genomes, the virus titer declined slightly in passage 2
but increased in passage 3–4 and remained at this level until the
end of the experiment (Fig. 5A). The chimeric viruses did not
reach the peak titer of wild type at any time point showing that
the chimera replicated with slower kinetics than the wild type.
The maximum titers of the wild type JFH1, P-p7 and F-p7 that
were achieved in this study were 7.4×107, 3.6×107 and
3.5×107 viral RNA copies/ml, respectively. The specific
infectivity of the wild type and F-p7 was calculated as 2900
and 1600 RNA copies per FFU, respectively. We also
determined the infectivity titers of the wild type and the
chimeric viruses of the supernatants up to passage 6 post-
transfection. Consistent with the results from the viral RNA
titers, the wild type virus reached its peak in early passages while
Pp7 and Fp7 chimeras reached their highest infectivity titers at
passage 3 and 5, respectively (Fig. 5B). Immunoblot analysis of
the cells transfected with wild type and chimeric genomes, and
the cells infected with the wild type and chimeric viruses did not
reveal a major difference in the pattern of proteins that reacted
with the monoclonal antibody AP33 (Fig. 6). This suggests that
the cleavage of E2 from its precursor protein was not affected by
the insertion and did not change during passaging the transfected
cells.
The heterologous p7 gene in the chimeric viruses is stable
RNA viruses commonly introduce compensatory mutations
in the heterologous genes to increase viral fitness. To investigate
if any mutation occurred in the HCV-A.p7 genes in the
backbone of JFH1, we examined the nucleotide sequences ofThe p7 protein is comprised of two luminal tails (LT) and two transmembrane
he JFH1 p7 sequences that were replaced by the corresponding regions in HCV-
Fig. 4. Wild type and chimeric genomes were replication-competent in transfected cells and produced infectious progeny. (A) Huh7 cells transfected with the in vitro
synthesized transcripts of GNDJFH1 (top panels), wild type JFH1 (second from top), mutant JFH1 encoding the entire HCV-A.p7 (F-p7, third from top) and mutant
JFH1 encoding the partial HCV-A.p7 (P-p7, bottom). Three days post-transfection, the cells were stained with anti-core antibody and counterstained with propidium
iodide. (B) Detection of HCV core protein by immunoblot analysis. The Huh7 cells were infected with the wild type and chimeric viruses. At day 3 post-infection, the
mock-infected and infected cells were directly lysed in 2× Laemmli buffer and subsequently subjected to SDS-PAGE in 12% gel. Negative: mock infected cells, JFH1:
wild type virus, P-p7: JFH1 encoding the partial HCV-A.p7, F-p7: JFH1 encoding the entire HCV-A.p7, PT: post-transfection, PI: post-infection, M: MagicMark
protein size marker (Invitrogen).
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from the cell culture supernatant of the passage 5 culture and
was subsequently used in a one step RT-PCR with genome-
specific primers, FE2 and RNS2 (Table 1). Agarose gel
electrophoresis of the PCR products from the chimeras showed
one distinct band with an electrophoretic mobility similar to that
of the product from the wild type virus (Fig. 7A). Nucleotide
sequencing of the products did not reveal any mutations in thesequence encoding p7 and flanking regions in the chimeric
viruses (Figs. 7B, C).
Amantadine reduced the wild type and chimeric virus titer in
the supernatant
It has been reported that the strain J4 of genotype 1b is
sensitive to amantadine (Griffin et al., 2003) while the JFH1
Fig. 6. Immunoblot analysis of the cells transfected with the wild type and
chimeric genomes or infected with the wild type and chimeric viruses. The same
number of cells was used in the transfection and infection experiments. 150 μl of
Laemmli buffer was added to each well of a 6-well plate, and 12 μl of each
sample was analyzed onto a 10% SDS-PAGE gel. The monoclonal antibody
AP33 was used to detect the E2 protein, 1: mock-transfected cells, 2: JFH1-
transfected cells, 3: Pp7-transfected cells, 4: Fp7-transfected cells, 5: JFH1
infected cells, 6: Pp7 infected cells, 7: Fp7 infected cells.
Fig. 5. Production of infectious HCV after transfection of the full-length RNA
transcripts of wild type and chimeric JFH1 into Huh7 cells RNA. Using
DMRIE-C (Invitrogen), 4 μg of the transcripts were transfected into Huh7 cells.
The supernatants were harvested at the indicated time points post-transfection.
(A) The virus titers in the supernatants were determined by a third-generation
HCV bDNA 3.0 assay (Bayer Diagnostics) as described in Materials and
methods. (B) The infectivity of the supernatants corresponding to the top figure
was determined, and the values were presented as focus forming unit (FFU) per
ml. GND: replication defective construct of JFH1, JFH1: JFH1 wild type, P-p7:
chimeric JFH1 genome encoding the partial HCV-A.p7, F-p7: chimeric JFH1
genome encoding the entire HCV-A.p7.
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2005). We investigated whether the full-length p7 chimera (F-
p7) with an identical TM1 to strain J4 is sensitive to amantadine.
As shown in Fig. 8, 30 μM amantadine reduced the wild type
and chimeric virus titer in the supernatant at day 3 post-infection
by about 0.3 and 0.25 log, respectively. This effect was not seen
at day 1 post-infection and was not due to amantadine-induced
cytotoxicity, as determined by the MTT assay (data not shown).
Discussion
This study describes the generation of two novel chimeric
viruses in which the partial or the entire p7 protein gene of the
JFH1 strain of HCV was substituted with the corresponding
gene from a genotype 1b virus (HCV-A). These novel chimeric
viruses are valuable tools for comparative studies of the
function of p7 in an authentic cell culture system and for the
examination of the effects of potential ion channel inhibitors in
vitro.
p7 protein is a small protein of HCV that is highly membrane
associated. The protein is comprised of two lumenal tails, two
TM domains with an intervening cytosolic loop. The lumenal
tails at the N- and C-termini of the protein were previously
reported to contain genotype-specific sequences since thechimeric 1a/2a virus was infectious only when the lumenal
tail sequences of the backbone genome of genotype 1a were left
unaltered in the chimeric genome (Sakai et al., 2003).
Differences in the amino acids of the N-terminal lumenal tails
of genotype 1a (H77C) and genotype 2a (J6) p7 proteins are
restricted to positions 4 and 9. In H77C, there are two polar
amino acids of asparagines at positions 4 and 9 while in J6 there
are two charged amino acids of lysine and histidine at the
corresponding positions (Sakai et al., 2003). The J4 p7, like the
HCV-A.p7, contains two asparagines at positions 4 and 9 while
JFH-1 p7, like J6 p7, contains a lysine and a histidine residue at
the corresponding positions, respectively. Moreover, the
differences between JFH1 and HCV-A in the C-terminal
lumenal tail are greater than the differences between J6 and
H77C (Sakai et al., 2003). Nevertheless, in the present study,
despite these differences, the full-length JFH1/HCV-A.p7
chimera was infectious and produced infectious particles. This
might reflect the difference between an in vivo and an in vitro
system to examine the chimeric HCV genomes. To further
examine the possibility of the existence of genotype-specific
sequences in the lumenal tails, the chimeric 1a/2a genomes can
now be examined in an in vitro assay since a cell culture system
is now available to grow genotype 1a and its chimeric viruses
(Yi et al., 2006). In this study, although the chimeric genomes
produced infectious viruses with comparable titers to wild type,
compared to the wild type, the chimeric viruses reached their
peak of infectivity with a delay. Sequencing analysis of the
insert regions did not reveal any compensatory mutation in the
p7 and flanking regions. Moreover, the immunoblot analysis did
not demonstrate a major difference in the processing of the E2-
p7-NS2 precursor proteins of the wild type and chimeras
following either transfection or infection. However, it is likely
that a compensatory mutation occurred in the viral genome,
outside of the p7 and flanking regions, which made the chimeric
viruses more replication-competent.
Until recently, HCV studies were hindered by the lack of a
robust cell culture system to grow the virus in vitro. Recently,
Wakita et al. (2005) reported a productive infection of Huh7 cells
with the JFH1 isolate of genotype 2a. Since then, Lindenbach
et al. (2005) generated a JFH1/J6 chimeric virus, containing
structural genes of J6 and NS genes of JFH1, and demonstrated
that the cells were productively infected with the chimera. Very
recently, Yi et al., (2006) demonstrated a complete replication
cycle of genotype 1a of HCV in cell culture. More recently,
Table 1
Name Position a Nucleotide sequence
FE2 2257–2276 GGTTGAGCACAGGCTCACGG
RNS2 2979–2998 CGGGCAGAATATAGTGACGG
F-FAus.p7 ACCACCACGGGCATACGCCTATGACGCACCTGTGCACGG
R-FAUS.p7 GGACCACCAGGTTCTCTAAGGCTGCTTCGGCCTGGCCCAAC
F-pAUS.p7 CTGCTCCTGCTGGCGCTACCACGGCAGGCTTATGCCTATGAC
R-pAUS.p7 AATGCCATGTGCTCCGGCCACACTCGCAGCGTGCAAGACG
M13 rev. primer CAGGAAACAGCTATGAC
HCV-A.p7 related sequences are in bold.
a Nucleotide positions are referred to full-length JFH1 genome (accession number: AB047639).
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encoding the genotype 1a, 1b and 3a structural proteins, p7 and
partial NS2 were also constructed (Koutsoudakis et al., 2006;
Pietschmann et al., 2006). Despite the importance of these
reports, the lack of a cell culture system to support the replication
of all the HCV genotypes remains a major obstacle to study
different HCV genotypes and develop antiviral drugs that are
effective against all genotypes. Moreover, in the current cell
culture systems, it is very difficult to justify the specific effects of
any ion channel inhibitors on the function of p7 protein.
Therefore, in the present study, based on the JFH1 strain, we
generated two novel chimeric viruses that encode only the
genotype 1b p7 gene to facilitate the comparative study of the ion
channel activity of the genotype 1 and 2 p7 proteins since
genotype 1 is responsible for a high proportion of HCV-infected
patients in most geographic areas. In most Asian countries,
genotype 1b is predominant while in the United States and
Europe genotype 1a and 1b are predominant (Bukh et al., 1995;
Lau et al., 1996). The ion channel activity of genotype 1b p7
protein (Yanagi et al., 1998) has been shown to be sensitive to
amantadine (Griffin et al., 2004). The amino acid sequence of theFig. 7. The p7 proteins in the chimeric viruses are stable. (A) The RNAwas extracte
(Pp7) and the entire p7 (Fp7) proteins and subjected to RT-PCR amplification. The P
were then sequenced, and the depicted amino acid sequences have been shown.J4 isolate only differs in two amino acid positions to the HCV-A
p7: one in the cytosolic loop and one in TM2 (Fig. 9). Using
computer modeling and electron microscopy, it has been
proposed that only TM1, but not TM2, is involved in ion
channel formation (Carrere-Kremer et al., 2002; Griffin et al.,
2003; Patargias et al., 2006). We have also examined the N-
terminal subunit of p7 for ion channel activity and confirmed the
previous reports by showing that the N-terminal subunit of p7
per se, independent from the C-terminal subunit, forms ion
channel in an artificial lipid bilayer (unpublished data).
Furthermore, J4 p7 has been shown to be sensitive to amantadine
in an artificial lipid bilayer and also in an in vitro system (Griffin
et al., 2003; Griffin et al., 2004). Computer modeling of the p7
protein of J4 strain demonstrated that amantadine resides within
the pore, formed by oligomerization of TM1, in the vicinity of
His-17 and interacts with Ser-21 via hydrogen bonding
(Patargias et al., 2006). Therefore, we examined the sensitivity
of the full-length chimeric virus, containing an identical N-
terminal subunit to the J4 strain p7 protein, for sensitivity to
amantadine. This study demonstrated that amantadine has a
similar effect on the life cycles of the chimeric (encoding the full-d from passage 4 of the wild type and the chimeric viruses containing partial p7
CR products were visualized in a 1% agarose gel. (B and C) The PCR products
Fig. 8. The effects of amantadine on the replication of wild type and chimeric
JFH1 (F-p7) viruses. Amantadine at a final concentration of 30 μMwas added to
the cell culture medium of Huh7 cells 1 h prior to and during the infection.
Supernatant samples were collected at day 1 and 3 post-infection as described in
Materials and methods. The virus titer was determined by a third-generation
HCV bDNA 3.0 assay (Bayer Diagnostics) as described in Materials and
methods. W-A: with amantadine, Wo-A: without amantadine.
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titer of the virus secreted into the supernatant. However, a much
larger reduction in the titer of the chimeric virus was expected,
due to the previous published data (see above). We also
demonstrated that the ion channel activity of the HCV-A
(genotype 1b) p7 protein was resistant to amantadine in artificial
lipid bilayers. The discrepancy between our results on HCV-A
(genotype 1b) and the published data on J4 p7 (genotype 1b)
may suggest a role for the cytosolic loop and TM2 in the
response to amantadine. To examine this, we are currently in the
process of changing the two amino acids to convert HCV-A.p7
to J4 p7. Although the results of the amantadine effect on JFH1
wild type are in contrast to previously published data (Steinmann
et al., 2005), they are in agreement with the more recentlyFig. 9. Comparison analysis of the deduced amino acid sequences of p7 proteins of J4published data showing that amantadine reduced the number of
JFH1 foci by about 70% in cell culture (Boume et al., 2005). The
mechanism of the effect of amantadine on the HCV life cycle is
not clear yet. However, the results presented in this manuscript
suggest that this mechanism is far more complex than simply
blocking ion channel pores. It has been documented that the
infection of cells with porcine circovirus type 2 that does not
contain any ion channel forming protein is inhibited by
amantadine through inhibition of clathrin-mediated endocytosis
(Nauwynck et al., 1999). HCV, like porcine circovirus type 2,
enters the cells via clathrin-mediated endocytosis (Blanchard
et al., 2006) and, therefore, the effect of amantadine on the HCV
life cycle might partially be through the blocking of this
function. Collectively, because the only difference between the
wild type and the chimera is the p7 protein and irrespective of the
sensitivity of p7 to amantadine, the drug has almost the same
effect on the viral life cycle, it is possible that this effect is not
through the inhibition of p7 protein.
In conclusion, we believe that the novel chimeric viruses
described in this manuscript are valuable tools for the study of
the function of the p7 protein and also to specifically examine
the effects of potential ion channel inhibitors in a genuine cell
culture system.
Materials and methods
Cells and plasmids
Huh7 cells were cultured in Dulbecco's modified Eagle's
medium (DMEM, Gibco/BRL, Gaithersburg, MD) supplemen-
ted with 10% fetal bovine serum (P.A. Biologicals Co.,
Melbourne, Australia), 100 IU of penicillin/ml and 100 μg of
streptomycin/ml. The wild type and replication-defective mutant
full-length JFH1 cDNA constructs were kindly provided by Dr.
Wakita (Wakita et al., 2005). The full-length Australian HCV
cDNA (HCV-A) was constructed in our laboratory (Trowbridge
and Gowans, 1998). E. coli strain JM109 (Promega, Madison,
Wis) was used in all transformation experiments.
Examination of HCV-A.p7 for ion channel activity and
amantadine sensitivity
A synthetic p7 peptide, based on the sequence of HCV-A, was
synthesized at GenScript Corporation (NJ, USA) and tested in an
planar lipid bilayers, as described previously (Premkumar et al.,
2004), to determine if it has ion channel activity. Similarly, a
peptide was synthesized corresponding to the N-terminal 38and HCV-A isolates of HCV. TM1 and TM2 are underlined (Sakai et al., 2003).
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YIKGRLVP) and was also examined for ion channel activity.
Amantadine sensitivity of the p7 ion channel was determined by
using 100 μM amantadine as described before (Premkumar
et al., 2004).
Construction of the recombinant cDNA
The full-length wild type and defective GNDmutant of JFH1
were digested with XbaI and NotI restriction enzymes, blunt
ended and re-circularized using standard protocols (Sambrook
et al., 1989). The recombinant plasmids were called wtJFH-N
and GJFH-N, respectively. Two chimeric JFH1/HCV-A.p7
fragments were then synthesized by fusion PCR, using the
primers shown in Table 1. In the first chimera, the entire p7 gene
of JFH1 was substituted by the HCV-A.p7. In the second, the
partial p7 protein (TM1, TM2 and cytosolic loop) of JFH1 was
replaced by the corresponding region of HCV-A to ensure that
the lumenal tails of the p7 protein of JFH1 remained unchanged.
The chimeric fragments were then digested with SphI and
cloned into the wtJFH-N and GJFH-N plasmids digested with
the corresponding enzyme to create 5′JFH-Fp7 and 5′JFH-Pp7
(containing the full-length and partial HCV-A.p7 genes),
respectively. These constructs were then digested with EcoRI
and KpnI, and the released fragments containing IRES, core,
E1, E2, partial or full-length HCV-A.p7 and NS2 were cloned
into wtJFH1 and mutant GNDJFH1 (digested with the
corresponding enzymes). The resultant recombinant JFH1
constructs were named J-Fp7 (JFH1 encoding full-length
HCV-A.p7), G-Fp7 (GNDJFH1 encoding full-length HCV-A.
p7), J-Pp7 (JFH1 encoding partial HCV-A.p7) and G-Pp7
(GNDJFH1 encoding partial HCV-A.p7). The nucleotide
sequences of the fragments were confirmed by using FE2 and
RNS2 primers (Table 1) in an automated cycle sequencing
reaction.
In vitro RNA transcription and transfection
RNA transcripts were synthesized as described (Huang et al.,
2005). To examine the replication competency of the recombi-
nant genomes, 4 μg of in vitro generated RNA transcripts was
transfected into cells in 6-well plates (Nalge Nunc, Rochester,
NY) using 10 μl of DMRIE-C (Invitrogen, Carlsbad, CA)
according to the manufacturer's instructions. The transfection
mixture was removed 5 h later, the cells washed twice with
DMEM and complete medium added. The cells were
trypsinized and passaged every 3–4 days for 7 passages as
described previously (Zhong et al., 2005).
Immunofluorescence (IF) and immunoblot analysis
The transfected and infected cells were fixed with cold
acetone for IF analysis then stained with goat anti-HCV core
antibody (ViroStat, Portland, ME) followed by Alexa Fluor
488-conjugated donkey anti-goat (Molecular Probes). The cells
were then counterstained with propidium iodide and examined
with a BioRad confocal microscope.For immunoblot analysis, the cells were directly lysed in 2×
Laemmli buffer (BioRad, Hercules, CA). Goat anti-HCV core
antibody and the monoclonal antibody AP33 (Owsianka et al.,
2005) were used to detect the HCV core and E2 proteins,
respectively. ECL Western blotting detection reagents (Amer-
sham Pharmacia Biosciences) were used according to the
manufacturer's instructions to detect the immunocomplexes.
Quantification of HCV RNA
The supernatant of each passage was filtered through a
0.45 μM filter and stored at −70 °C. From each passage, 75 μl
of the supernatant fluids was collected and 50 μl of aliquots
used for quantification. HCV viral loads were determined using
the Versant HCV RNA 3.0 bDNA assay (Bayer HealthCare,
Tarrytown, NY) according to the manufacturer's instructions.
Amantadine treatment of wild type and chimeric viruses
infected cells
Overnight cultures of Huh7 cells were treated with
amantadine (Sigma) at final concentrations of 30 μM for 1 h
that was not toxic for the cells in an MTT-based cytotoxicity
assay (data not shown). The cells were then infected with the
wild type and chimeric JFH1 samples containing 3.5×106 and
2.5×106 RNA copies/ml, respectively, in the presence of
amantadine for 5 h. The cells were washed twice with DMEM,
and fresh medium containing 30 μM amantadine was added. To
determine whether amantadine has any effect on the progeny
virus production, the cells were grown for 3 days and 200 μl
samples collected on day 1 and 3 post-infection for quantifica-
tion of HCV RNA. After each sampling, a same volume of fresh
medium containing amantadine was added to each culture.
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